Detalles de la búsqueda
1.
A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.
Eur Urol
; 52(5): 1398-406, 2007 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-17485161
2.
Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial.
J Urol
; 174(4 Pt 1): 1242-7, 2005 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-16145378
Resultados
1 -
2
de 2
1
Próxima >
>>